Novo Nordisk AS
NOV
Company Profile
Business description
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Contact
Novo Alle 1
Bagsvaerd2880
DNKT: +45 44448888
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
69,500
Stocks News & Analysis
stocks
Sales shine but broader macro outlook darkens for this ASX share
US stores are struggling, but our investment thesis hinges on the Australian rollout.
stocks
Chart of the Week: US equity market trading at an attractive discount
The latest from our Chief US Market Strategist.
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,154.90 | 8.80 | -0.10% |
| CAC 40 | 8,263.87 | 355.13 | 4.49% |
| DAX 40 | 24,080.63 | 1,159.04 | 5.06% |
| Dow JONES (US) | 47,909.92 | 1,325.46 | 2.85% |
| FTSE 100 | 10,608.88 | 260.09 | 2.51% |
| HKSE | 25,788.81 | 104.21 | -0.40% |
| NASDAQ | 22,634.99 | 617.14 | 2.80% |
| Nikkei 225 | 55,998.59 | 309.83 | -0.55% |
| NZX 50 Index | 13,273.81 | 19.87 | 0.15% |
| S&P 500 | 6,782.81 | 165.96 | 2.51% |
| S&P/ASX 200 | 8,957.50 | 15.30 | -0.17% |
| SSE Composite Index | 3,965.27 | 29.73 | -0.74% |